IN2014MN01937A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01937A
IN2014MN01937A IN1937MUN2014A IN2014MN01937A IN 2014MN01937 A IN2014MN01937 A IN 2014MN01937A IN 1937MUN2014 A IN1937MUN2014 A IN 1937MUN2014A IN 2014MN01937 A IN2014MN01937 A IN 2014MN01937A
Authority
IN
India
Prior art keywords
subject
metabolic syndrome
diabetes mellitus
risk
level
Prior art date
Application number
Other languages
English (en)
Inventor
Andreas Bergmann
Olle Melander
Original Assignee
Sphingotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh
Publication of IN2014MN01937A publication Critical patent/IN2014MN01937A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1937MUN2014 2012-03-08 2013-03-08 IN2014MN01937A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261608350P 2012-03-08 2012-03-08
EP12158680 2012-03-08
EP12165062 2012-04-20
PCT/EP2013/054801 WO2013132090A1 (fr) 2012-03-08 2013-03-08 Méthode de prédiction du risque que présente un sujet de contracter le diabète sucré et/ou le syndrome métabolique ou méthode de diagnostic du syndrome métabolique chez un sujet

Publications (1)

Publication Number Publication Date
IN2014MN01937A true IN2014MN01937A (fr) 2015-07-10

Family

ID=49115970

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1937MUN2014 IN2014MN01937A (fr) 2012-03-08 2013-03-08

Country Status (9)

Country Link
US (2) US10520512B2 (fr)
EP (1) EP2823316B1 (fr)
JP (1) JP6262669B2 (fr)
CN (1) CN103308670B (fr)
ES (1) ES2684512T3 (fr)
IN (1) IN2014MN01937A (fr)
RU (1) RU2685713C2 (fr)
TR (1) TR201811201T4 (fr)
WO (1) WO2013132090A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3002589A1 (fr) * 2014-10-01 2016-04-06 sphingotec GmbH Procédé de stratification d'un sujet femelle pour de l'hormonothérapie substitutive
SG11201706460QA (en) * 2015-02-27 2017-09-28 Sphingotec Gmbh A method for predicting the risk of obesity in a subject
US10473670B2 (en) 2016-02-25 2019-11-12 University Of Kentucky Research Foundation Method of predicting obesity comprising measuring neurotensin
WO2022203533A1 (fr) * 2021-03-25 2022-09-29 Владимир Валерьевич ВОЛОБУЕВ Procédé d'estimation de la prédisposition à diverses formes du diabète sucré de type 2

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5430047A (en) * 1994-04-07 1995-07-04 Warner-Lambert Company Neurotensin antagonists
EP0803255A4 (fr) * 1994-06-03 1999-06-30 Tsumura & Co Composition medicinale
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6248527B1 (en) * 1998-10-21 2001-06-19 Millennium Pharmaceuticals, Inc. Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
CA2455300A1 (fr) * 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe
MXPA04001804A (es) 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Proteinas de fusion de transferrina modificada.
ATE528014T1 (de) 2002-06-07 2011-10-15 Dyax Corp Polypeptid mit modifizierten kunitz domains
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
EP1793847A2 (fr) 2004-09-21 2007-06-13 NascaCell IP GmbH Utilisation de microproteines en tant qu'inhibiteurs d'une tryptase
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
WO2006110082A1 (fr) * 2005-04-11 2006-10-19 Astrazeneca Ab Methode et trousse de diagnostic du diabete de type 2, du syndrome metabolique, de l'atherosclerose subclinique, de l'infarctus du myocarde, d'un accident cerebrovasculaire ou des signes cliniques du diabete
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
CA2742241C (fr) 2008-11-03 2019-12-10 Molecular Partners Ag Proteines de liaison inhibant l'interaction du recepteur vegf-a
CA2745524C (fr) * 2008-12-05 2020-06-09 Angiochem Inc. Conjugues de neurotensine ou d'analogues de neurotensine et leurs applications
US8586043B2 (en) 2009-01-07 2013-11-19 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1
CA2772162C (fr) 2009-08-27 2018-05-22 Covagen Ag Fynomer anti-il-17a et leurs usages medicaux
WO2011059721A1 (fr) * 2009-10-29 2011-05-19 Tethys Bioscience, Inc. Biomarqueurs de protéines et de lipides améliorant considérablement la prédiction du diabète de type 2
US8748351B2 (en) 2009-12-14 2014-06-10 Scil Proteins Gmbh Method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
UA58612U (uk) * 2010-06-04 2011-04-26 Высшее Государственное Учебное Заведение «Украинская Медицинская Стоматологическая Академия» Спосіб діагностики інсулінорезистентності у хворих на метаболічний синдром та цукровий діабет 2 типу
ES2729652T3 (es) 2010-06-08 2019-11-05 Pieris Pharmaceuticals Gmbh Muteína de lipocalina lacrimal unidas a IL-4R alpha
SG11201706460QA (en) * 2015-02-27 2017-09-28 Sphingotec Gmbh A method for predicting the risk of obesity in a subject

Also Published As

Publication number Publication date
CN103308670A (zh) 2013-09-18
RU2685713C2 (ru) 2019-04-23
EP2823316A1 (fr) 2015-01-14
US20150056203A1 (en) 2015-02-26
JP2015512048A (ja) 2015-04-23
RU2014140427A (ru) 2016-04-27
CN103308670B (zh) 2017-06-09
TR201811201T4 (tr) 2018-09-21
US10520512B2 (en) 2019-12-31
EP2823316B1 (fr) 2018-05-23
ES2684512T3 (es) 2018-10-03
JP6262669B2 (ja) 2018-01-17
WO2013132090A1 (fr) 2013-09-12
US20200326350A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
EA201590027A1 (ru) Способы детекции заболеваний или состояний
WO2013084002A3 (fr) Procédé de détection de produits d'addition à base de nucléosomes
BR112013000760A2 (pt) método e aparelho para medir a espessura do tecido adiposo
WO2013159872A8 (fr) Biomarqueurs pour le diagnostic, le pronostic, l'évaluation et la stratification thérapeutique d'une syncope
NZ601590A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013030578A3 (fr) Procédé de détection de nucléosomes
IN2014MN01937A (fr)
NZ630421A (en) Biomarkers predictive for clinical response for glatiramer acetate
BR112015003046A2 (pt) sistema de neurofeedback, processador de sinal para determinação de uma característica do sinal do sinal do biofeedback medido, método para provisão de um usuário com o neurofeedback e programa de computador.
WO2010041046A8 (fr) Protéines de granine en tant que marqueurs de maladie cardiaque
WO2014004889A3 (fr) Diagnostic de prédiction d'analytes du plasma et pronostic d'un anévrisme de l'aorte thoracique
WO2014053466A3 (fr) Système et procédé pour l'évaluation du risque associé à une glycémie
WO2014078468A3 (fr) Biomarqueurs destinés à prédire une réponse clinique de patients cancéreux suite à un traitement avec un agent immunothérapeutique
MX359328B (es) Metodo para el diagnostico de enfermedad de niemann-pick.
IN2014MN01940A (fr)
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
WO2014187884A3 (fr) Micro-arn servant de biomarqueurs non invasifs de l'insuffisance cardiaque
RU2010145662A (ru) Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
WO2016066862A3 (fr) Méthode de prédiction du risque d'obésité chez un sujet
WO2015192854A3 (fr) Méthodes et outils de prédiction d'une stéatose hépatique
WO2011085057A3 (fr) Procédés pour la détection d'auto-anticorps anti-insuline
WO2015069883A8 (fr) Fraction oxydée de l'adn extracellulaire utilisable en tant que biomarqueur du stress et ses procédés d'utilisation
WO2013101276A3 (fr) Diagnostic et détection de conditions pathologiques modulées par l'activation de la voie des sphingolipides
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
WO2015010042A3 (fr) Méthode de détermination du risque de glycémie égale ou supérieure à 140 mg/di en 2 heures